NCT06243510Completed
Comparison of Apixaban Versus Enoxaparin
Comparison of Apixaban Versus Enoxaparin as Venous Thromboembolism Prophylaxis After Radical Cystectomy
Source: ClinicalTrials.gov · Last updated 23 Jun 2026
Brief summary (registry, in English)
The goal of this randomized trial is to compare bladder cancer patient experiences taking prophylactic anticoagulation at home after surgery to remove their bladder. The main questions it aims to answer are: * Are patients equally adherent to apixaban as they are enoxaparin? Why or why not? * Do patients prefer apixaban or enoxaparin? * What is the typical patient cost to take apixaban vs enoxaparin after surgery? Participants will be randomized to receive a prescription for either enoxaparin or apixaban which they will then fill themselves and self-administer at home until post-operative day 30. They will receive phone calls from study coordinators at days 30 and 90 to complete questionaries over the phone to assess trial outcomes.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 126 (actual)
- First submitted
- 23 Jan 2024
- Start date
- 24 Nov 2023
- Primary completion date
- 30 Jan 2026
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Diseases
- Bladder cancer
- NCT number
- NCT06243510
What you commit to
- Study type: Interventional
- Participants enrolled: 126
- From 24 Nov 2023 to the primary completion date, 30 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Failure to undergo radical cystectomy with concurrent urinary diversion and pelvic lymph node dissection
- Any medical condition which precludes treatment with either enoxaparin or apixaban (including dialysis, hemophilia or any other bleeding diathesis)
Other illness
- Failure to be discharged by post-operative day 14
- Failure to receive a script for enoxaparin or apixaban.
Other
- Preoperative use of a therapeutic dose of anticoagulant (this notably does not exclude patients taking antiplatelet agents)
Who the study is looking for
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Able to communicate in English over the phone
- Male or female, age \>18 years
- Diagnosed with biopsy-proven, urothelial cell carcinoma (any T stage, N0-1, M0) with plan for radical cystectomy with urinary diversion and concurrent pelvic lymph node dissection as treatment
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital of the University of Pennsylvania Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.